DK0812206T3 - Fremgangsmåde til stimulering af en immunrespons - Google Patents

Fremgangsmåde til stimulering af en immunrespons

Info

Publication number
DK0812206T3
DK0812206T3 DK96909555T DK96909555T DK0812206T3 DK 0812206 T3 DK0812206 T3 DK 0812206T3 DK 96909555 T DK96909555 T DK 96909555T DK 96909555 T DK96909555 T DK 96909555T DK 0812206 T3 DK0812206 T3 DK 0812206T3
Authority
DK
Denmark
Prior art keywords
immune response
stimulating
individuals
pathogenic
ligand
Prior art date
Application number
DK96909555T
Other languages
English (en)
Inventor
Charles R Maliszewski
Mark Alderson
Kim A Campbell
Mary K Kennedy
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0812206T3 publication Critical patent/DK0812206T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
DK96909555T 1995-03-01 1996-02-29 Fremgangsmåde til stimulering af en immunrespons DK0812206T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01
PCT/US1996/002839 WO1996026735A1 (en) 1995-03-01 1996-02-29 Method for stimulating an immune response

Publications (1)

Publication Number Publication Date
DK0812206T3 true DK0812206T3 (da) 2002-09-09

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96909555T DK0812206T3 (da) 1995-03-01 1996-02-29 Fremgangsmåde til stimulering af en immunrespons

Country Status (15)

Country Link
EP (1) EP0812206B1 (da)
JP (1) JP3657271B2 (da)
KR (1) KR19980702490A (da)
AT (1) ATE220331T1 (da)
AU (1) AU699291B2 (da)
CA (1) CA2213798C (da)
DE (1) DE69622259T2 (da)
DK (1) DK0812206T3 (da)
ES (1) ES2179187T3 (da)
FI (1) FI973484L (da)
MX (1) MX9706588A (da)
NO (1) NO973875L (da)
NZ (1) NZ305083A (da)
PT (1) PT812206E (da)
WO (1) WO1996026735A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022008A1 (en) * 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
IL136731A0 (en) * 1997-12-19 2001-06-14 Immunex Corp Method for reducing susceptibility to hiv infection
ATE304375T1 (de) * 1998-05-23 2005-09-15 Univ Leiden Medical Ct Cd40 bindende antikörper und ctl peptide zur behandlung von tumoren
CA2399790C (en) 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
PL2066339T3 (pl) 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT3097926T (pt) 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
AR094791A1 (es) 2013-02-14 2015-08-26 Univ Arkansas Composiciones y métodos para mejorar las respuestas inmunes ante una infección por eimeria o para limitar una infección por eimeria
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2198025T3 (es) * 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
AU5098493A (en) * 1992-08-21 1994-03-15 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
NZ273504A (en) * 1993-10-01 1997-12-19 Immunex Corp Monoclonal antibodies (moabs) that specifically bind human cd40 molecules and cd40 ligand binding

Also Published As

Publication number Publication date
DE69622259T2 (de) 2003-03-27
NO973875D0 (no) 1997-08-22
DE69622259D1 (de) 2002-08-14
EP0812206B1 (en) 2002-07-10
JP3657271B2 (ja) 2005-06-08
WO1996026735A1 (en) 1996-09-06
CA2213798A1 (en) 1996-09-06
FI973484A7 (fi) 1997-10-24
CA2213798C (en) 2001-02-06
KR19980702490A (ko) 1998-07-15
ES2179187T3 (es) 2003-01-16
AU5301196A (en) 1996-09-18
EP0812206A1 (en) 1997-12-17
JPH11506418A (ja) 1999-06-08
FI973484A0 (fi) 1997-08-25
NO973875L (no) 1997-10-31
NZ305083A (en) 1999-06-29
ATE220331T1 (de) 2002-07-15
PT812206E (pt) 2002-11-29
FI973484L (fi) 1997-10-24
AU699291B2 (en) 1998-11-26
MX9706588A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
DK0724456T3 (da) CD40-Antistoffer
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
DE69316948D1 (de) Lösliche Liganden für CD40
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
EP1266965A3 (en) Recombinant antibodies for human therapy
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
CA2429027A1 (en) Antibodies against human receptor h4-1bb
IL221708A0 (en) Polyclonal goat anti-hla class ii antibody for treatment of disease involving proliferative immune response
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
NO971059L (no) Modifiserte human-C3-proteiner
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
EA199700196A1 (ru) Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом
ATE309371T1 (de) Protein mit dnase-aktivität
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
NZ314010A (en) A method of targeting intracellular binding proteins using a lipidized antibody